产品
编 号：F370776
分子式：C37H56O10
分子量：660.83
分子式：C37H56O10
分子量：660.83
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 501938-01-8
产品详情
生物活性：
23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
体内研究：
23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice.23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.Animal Model:Diet induced obesity in C57BL/6 mice.
Dosage:1-10 mg/kg.
Administration:Orally, daily for 12 weeks.
Result:Lowered body weight gain, fat mass, and liver weight.5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.
体外研究：
23-epi-26-Deoxyactein (DA :10 μM and 20 μM) inhibits 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα, C/ebpβ, and Pparγ, which are the critical adipogenic transcription factors.23-epi-26-Deoxyactein (DA) promotes mitochondrial biogenesis in pancreatic β-cells preventing methylglyoxal-induced oxidative cell damage and protects osteoblasts against Antimycin A-induced cell damage.23-epi-26-Deoxyactein (DA) inhibits growth of the MCF7 human breast cancer cells and induces cell cycle arrest at G1 (IC50 of 21μM).23-epi-26-Deoxyactein (0.1-1 μM) protects osteoblasts against Antimycin A-induced cell damage.
23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
体内研究：
23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice.23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.Animal Model:Diet induced obesity in C57BL/6 mice.
Dosage:1-10 mg/kg.
Administration:Orally, daily for 12 weeks.
Result:Lowered body weight gain, fat mass, and liver weight.5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.
体外研究：
23-epi-26-Deoxyactein (DA :10 μM and 20 μM) inhibits 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα, C/ebpβ, and Pparγ, which are the critical adipogenic transcription factors.23-epi-26-Deoxyactein (DA) promotes mitochondrial biogenesis in pancreatic β-cells preventing methylglyoxal-induced oxidative cell damage and protects osteoblasts against Antimycin A-induced cell damage.23-epi-26-Deoxyactein (DA) inhibits growth of the MCF7 human breast cancer cells and induces cell cycle arrest at G1 (IC50 of 21μM).23-epi-26-Deoxyactein (0.1-1 μM) protects osteoblasts against Antimycin A-induced cell damage.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备